Latest News and Press Releases

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be...

Basel, 30. Januar 2025 Konzernverkäufe stiegen um 7%1 zu konstanten Wechselkursen (CER; 3% in CHF) dank hoher Nachfrage sowohl nach Medikamenten als auch nach Diagnostika.Ohne COVID-19-Produkte...

Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%....

Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas...

Updated overall survival (OS) results - a key secondary endpoint - reinforce the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positive,...

Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to Rise (TTR) and 10-meter walk/run (10MWR), results were statistically significant and clinically meaningful two...

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to...

Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and...

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpointsPrasinezumab continues to be well tolerated and no new safety signals were...

Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical labClinical mass spectrometry testing offers unparalleled sensitivity and specificity, providing...